SW1271 Cells

The SW1271 cell line is a human small cell lung carcinoma (SCLC) model derived from an adult patient. It is characterized by its neuroendocrine phenotype, which is typical of SCLC, and displays molecular features relevant to therapeutic sensitivity and resistance. In a comprehensive epigenome-wide methylation analysis of SCLC cell lines, including SW1271, the line exhibited specific DNA methylation patterns that correlated with chemosensitivity to several classes of anticancer drugs. These included Aurora kinase inhibitors, CDK inhibitors, and DNA-damaging agents. The methylation status of key genes such as TREX1, SLFN11, CEP350, and KDM1A in SW1271 and other SCLC models has been associated with altered drug response, implicating epigenetic modulation as a determinant of therapeutic efficacy.

Furthermore, SW1271 has been used in integrated genomic and epigenomic studies to understand subtype-specific vulnerabilities in SCLC. This cell line, along with others representing different SCLC transcriptional subtypes (ASCL1, NEUROD1, POU2F3, and YAP1), helps delineate the heterogeneity within the disease. The methylation profile of SW1271 contributes to our understanding of the regulatory mechanisms affecting gene expression and drug response, including suppression of tumor suppressor genes and dysregulation of lineage-specific transcription factors. These insights position SW1271 as a valuable model for investigating epigenetically driven pathways in SCLC and for identifying potential biomarkers and therapeutic targets.